Literature DB >> 10563669

Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples.

G Ragnarsson1, G Bodemar.   

Abstract

BACKGROUND: If subgroups exist in a sample of patients with irritable bowel syndrome (IBS), they may represent different etiologic and pathophysiologic entities. Our aim was to identify subgroups on the basis of symptoms in IBS.
METHODS: Two independent groups of 56 (sample I) and 52 (sample II) outpatients recorded their abdominal symptoms daily for 6 weeks and 1 week, respectively. The daily records were assessed by using cluster analysis.
RESULTS: Similar subgroups appeared in both samples. Three bowel habit subgroups were identified. The first was distinguished by hard stools, varying stool consistency, and highly disturbed stool passage, the second by loose stools and urgency, and the third by normal stools and the least disturbed stool passage. Two pain/bloating subgroups were identified, one distinguished by little and the other by considerable pain and bloating. No relation was found between pain/bloating and bowel habit subgroup membership. Most patients had stool frequency within the normal range regardless of subgroup. In sample I the subgroups had stable symptoms during the study, and subgroup placement was not related to the presence of dyspepsia, smoking habits, or use of bulk agent and/or sporadic intake of loperamide. The degree of pain and bloating was inversely related to illness duration.
CONCLUSIONS: Subgroups exist in IBS. Division of IBS into bowel habit subgroups should be based on stool consistency, not frequency. Mechanisms mediating pain and bloating may be different from those mediating symptoms at defecation.

Entities:  

Mesh:

Year:  1999        PMID: 10563669     DOI: 10.1080/003655299750025093

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  21 in total

Review 1.  Serotonergic modulating drugs for functional gastrointestinal diseases.

Authors:  Robin Spiller
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

2.  Cluster's last stand.

Authors:  S C Howell; G D Eslick; N J Talley
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 3.  Expert commentary--bloating, distension, and the irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  MedGenMed       Date:  2005-01-10

4.  Multi-Dimensional Gastrointestinal Symptom Severity Index: Validation of a Brief GI Symptom Assessment Tool.

Authors:  Michael D Crowell; Sarah B Umar; Brian E Lacy; Michael P Jones; John K DiBaise; Nicholas J Talley
Journal:  Dig Dis Sci       Date:  2015-04-05       Impact factor: 3.199

Review 5.  The role of gender and biological sex in irritable bowel syndrome.

Authors:  Christine L Frissora; Kenneth L Koch
Journal:  Curr Gastroenterol Rep       Date:  2005-08

6.  Treatment of Irritable Bowel Syndrome.

Authors:  Robin C. Spiller
Journal:  Curr Treat Options Gastroenterol       Date:  2003-08

Review 7.  Role of serotonin in the pathophysiology of the irritable bowel syndrome.

Authors:  Michael D Crowell
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

8.  Rectal hypersensitivity reduced by acupoint TENS in patients with diarrhea-predominant irritable bowel syndrome: a pilot study.

Authors:  Wen-Bin Xiao; Yu-Lan Liu
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

9.  Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores.

Authors:  Jeffrey M Lackner; James Jaccard; Charles Baum
Journal:  Value Health       Date:  2012-11-30       Impact factor: 5.725

10.  Depression, anxiety and anger in subtypes of irritable bowel syndrome patients.

Authors:  Maria Rosaria A Muscatello; Antonio Bruno; Gianluca Pandolfo; Umberto Micò; Simona Stilo; Mariagrazia Scaffidi; Pierluigi Consolo; Andrea Tortora; Socrate Pallio; Giuseppa Giacobbe; Luigi Familiari; Rocco Zoccali
Journal:  J Clin Psychol Med Settings       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.